No products in the cart.
Pre-made Apolizumab benchmark antibody (Whole mAb, anti-HLA-DRB/HLA-DRB1 therapeutic antibody, Anti-DRB1/SS1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-736
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-HLA-DRB/HLA-DRB1 therapeutic antibody (Pre-made Apolizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 25 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.[3] There are no current clinical trials into its use.[4]
| Products Name (INN Index) | Pre-Made Apolizumab Biosimilar, Whole Mab, Anti-HLA-DRB/HLA-DRB1 Antibody: Anti-DRB1/SS1 therapeutic antibody |
|---|---|
| INN Name | apolizumab |
| Target | HLA-DRB |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | PDL?(Protein Design?Labs) BioPharma (Fremont CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | HLA-DRB |
| Package |
Previous slide
Next slide
